VBS Stock Overview
Engages in the medical research and development activities in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Vectus Biosystems Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.077 |
| 52 Week High | AU$0.26 |
| 52 Week Low | AU$0.076 |
| Beta | 0.91 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -96.22% |
| 5 Year Change | n/a |
| Change since IPO | -92.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| VBS | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | 0.9% |
| 1Y | n/a | 11.0% | 18.4% |
Return vs Industry: Insufficient data to determine how VBS performed against the Australian Biotechs industry.
Return vs Market: Insufficient data to determine how VBS performed against the Australian Market.
Price Volatility
| VBS volatility | |
|---|---|
| VBS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: VBS's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: Insufficient data to determine VBS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | n/a | www.vectusbiosystems.com.au |
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure; VB4-A32 for the treatment of liver fibrosis; VB4-A79 for the treatment of lung fibrosis; and VB4-P5 for the treatment of renal fibrosis.
Vectus Biosystems Limited Fundamentals Summary
| VBS fundamental statistics | |
|---|---|
| Market cap | AU$4.26m |
| Earnings (TTM) | -AU$2.34m |
| Revenue (TTM) | AU$1.14m |
3.7x
P/S Ratio-1.8x
P/E RatioIs VBS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VBS income statement (TTM) | |
|---|---|
| Revenue | AU$1.14m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$1.14m |
| Other Expenses | AU$3.48m |
| Earnings | -AU$2.34m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.044 |
| Gross Margin | 100.00% |
| Net Profit Margin | -205.34% |
| Debt/Equity Ratio | 0% |
How did VBS perform over the long term?
See historical performance and comparison